Across TCGA pan-cancer cohorts, PAK4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PAK4 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher PAK4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAK4 expression acts as an unfavorable survival marker.
SCLC and SKCM are the cancer types where PAK4 Mutation most reproducibly stratifies survival.